Loading…

Synthesis and bioevaluation of aryl hydroxamates distinguishing between NAD+ and ATP-dependent DNA ligasesElectronic supplementary information (ESI) available: Experimental procedures, characterization data and copies of 1H NMR and 13C NMR spectra, protocols of biological assays. See DOI: 10.1039/c2md00168c

Identification of compounds distinguishing between NAD + and ATP-dependent ligases is a key factor to discover new antimicrobials. Based on virtual screening experiments a series of hydroxamates distinguishing between the above two classes of enzymes are synthesized. The specificity of the compounds...

Full description

Saved in:
Bibliographic Details
Main Authors: Kukshal, Vandna, Mishra, Mridul, Ajay, Arya, Khanam, Taran, Sharma, Rahul, Dube, Divya, Chopra, Deepti, Tripathi, Rama Pati, Ramachandran, Ravishankar
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Identification of compounds distinguishing between NAD + and ATP-dependent ligases is a key factor to discover new antimicrobials. Based on virtual screening experiments a series of hydroxamates distinguishing between the above two classes of enzymes are synthesized. The specificity of the compounds for the bacterial LigA was tested in vivo involving a temperature sensitive LigA deficient E. coli GR501 strain rescued with the M. tuberculosis LigA ( Mtu LigA) and a wild type S. typhimurium and its LigA-strain rescued with T4 ligase. The compounds exhibit similar specificity for the NAD + -dependent ligases. In vitro assays involving the Mtu LigA and the human DNA ligase I enzymes show that two compounds are 8-fold specific at low M concentrations. Ethidium bromide displacement assays indicate that the compounds do not exhibit general interactions with DNA. The overall study suggests that hydroxamates have the potential to be developed as novel antibacterials. Identification of low molecular weight hydroxamates as Mycobacterial NAD-LigA inhibitors via virtual screening and in vitro screen protocol.
ISSN:2040-2503
2040-2511
DOI:10.1039/c2md00168c